Evidence map›Paper›PMID 40549915›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2025

Spatial metabolomics informs the use of clinical imaging for improved detection of cribriform prostate cancer.

Nikita Sushentsev, Gregory Hamm, Roido Manavaki, Mary A McLean, Jonathan Birchall, Dmitry Soloviev, David Y Lewis, Luigi Aloj, Lucy Flint, Aleksandr Zakirov and 7 more

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Advances in spatial omics for the analysis of prostate cancer.Analytical and bioanalytical chemistry · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Nikita Sushentsev *Department of Radiology, Addenbrooke's Hospital and University of Cambridge, Cambridge Biomedical Campus, Cambridge CB2 0QQ, United Kingdom.ORCID 0000-0003-4500-9714
Gregory Hamm *Integrated BioAnalysis, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, United Kingdom.
Roido ManavakiDepartment of Radiology, Addenbrooke's Hospital and University of Cambridge, Cambridge Biomedical Campus, Cambridge CB2 0QQ, United Kingdom.ORCID 0000-0002-4384-6626
Mary A McLeanDepartment of Radiology, Addenbrooke's Hospital and University of Cambridge, Cambridge Biomedical Campus, Cambridge CB2 0QQ, United Kingdom.
Jonathan BirchallDepartment of Radiology, Addenbrooke's Hospital and University of Cambridge, Cambridge Biomedical Campus, Cambridge CB2 0QQ, United Kingdom.
Dmitry SolovievLewis Group, School of Cancer Sciences, University of Glasgow, Glasgow G61 1BD, United Kingdom.ORCID 0000-0002-1324-3197
David Y LewisLewis Group, School of Cancer Sciences, University of Glasgow, Glasgow G61 1BD, United Kingdom.
Luigi AlojDepartment of Radiology, Addenbrooke's Hospital and University of Cambridge, Cambridge Biomedical Campus, Cambridge CB2 0QQ, United Kingdom.ORCID 0000-0002-7452-4961
Lucy FlintIntegrated BioAnalysis, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, United Kingdom.
Aleksandr ZakirovDepartment of Clinical Neurosciences, University of Cambridge, Cambridge CB2 0QQ, United Kingdom.
Ian G MillsNuffield Department of Surgical Sciences, University of Oxford, Oxford OX3 9DU, United Kingdom.ORCID 0000-0001-5347-5083
Vincent J GnanapragasamDepartment of Urology, Cambridge University Hospitals National Health Service Foundation Trust, Cambridge CB2 0QQ, United Kingdom.
Anne Y WarrenDepartment of Pathology, Cambridge University Hospitals National Health Service Foundation Trust, Cambridge CB2 0QQ, United Kingdom.
Simon T BarryBioscience, Discovery, Oncology Research and Development, AstraZeneca, Cambridge CB2 0AA, United Kingdom.
Richard J A Goodwin *Integrated BioAnalysis, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, United Kingdom.ORCID 0000-0001-5699-8488
Ferdia A Gallagher *Department of Radiology, Addenbrooke's Hospital and University of Cambridge, Cambridge Biomedical Campus, Cambridge CB2 0QQ, United Kingdom.
Tristan Barrett *Department of Radiology, Addenbrooke's Hospital and University of Cambridge, Cambridge Biomedical Campus, Cambridge CB2 0QQ, United Kingdom.ORCID 0000-0002-1180-1474

Funding

NIHR | NIHR Cambridge Biomedical Research Centre (NIHR Cambridge BRC) NIHR203312Prostate Cancer UK (ProstateUK) PA14-012
6 · The paper itself

Abstract

Cribriform prostate cancer (crPCa) is associated with poor clinical outcomes, yet its accurate detection remains challenging due to the poor sensitivity of standard-of-care diagnostic tools. Here, we use untargeted spatial metabolomics to identify fatty acid biosynthesis as a key metabolic pathway enriched in crPCa epithelium. We also show that imaging tumor lipid metabolism using [1-

Indexed as

MetabolomicsProstatic NeoplasmsAgedFatty AcidsHumansLipid MetabolismMaleMiddle AgedPositron Emission Tomography Computed TomographyProspective StudiesFatty Acidscancer metabolismMRInuclear medicineprostate cancerspectroscopy

Identifiers

PMID40549915
PMCPMC12232551

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.